7C8 Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.02 - €0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)14.00
Market Cap
€2.66M
Enterprise Value€4.97M
Total Cash (Recent Filing)€137.54K
Total Debt (Recent Filing)€627.68K
Price to Earnings (P/E)―
Beta-0.51
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding109,200,640
10 Day Avg. Volume40
30 Day Avg. Volume14
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetNo reported debt materially reduces ongoing interest burden and financial distress risk, giving management flexibility to prioritize R&D spending and licensing strategy. This durable conservatism supports the company through multi-quarter clinical development cycles without immediate solvency pressure.
Focused Clinical-stage AssetA clear, focused pipeline centered on IVX-P02 PDT creates a concentrated development strategy and makes partnership or licensing deals more straightforward. Specialised modality in oncology can command strategic interest from larger pharmas, enabling non-dilutive commercialization paths over the medium term.
Improving Free Cash Flow TrendAn improvement in free cash flow versus the prior year signals early operational efficiency gains or reduced discretionary spend. While FCF remains negative, a durable improvement trend lessens near-term funding stress and supports extension of the development runway before next financing.
Bears Say
Revenue CollapseA move to zero revenue eliminates internal validation of commercial routes and removes any offset to R&D and G&A costs. For an early-stage biotech, absent revenue increases dependency on external capital, raising dilution and slowing development cadence over the next several quarters.
Persistent Cash BurnConsistent negative operating cash flow and free cash flow indicate ongoing reliance on financing to fund operations and trials. This structural cash burn increases the probability of equity raises or other funding that can dilute investors and constrain long-term R&D planning.
Eroding Equity And AssetsSignificant declines in equity and total assets reflect cumulative losses that reduce financial flexibility and the firm’s capacity to withstand clinical setbacks. Lower asset and equity bases limit collateral for financing and heighten vulnerability to capital-market conditions over months ahead.
Invion News
7C8 FAQ
What was Invion’s price range in the past 12 months?
Invion lowest stock price was €0.02 and its highest was €0.09 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is €2.66M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Aug 27, 2026 which is in 23 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Feb 26, 2026. The company reported -€0.026 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.026.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 109,200,640 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -€0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in DE:7C8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:7C8 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.10%
Trailing 12-Months
Company Description
Invion
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―